Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: dates

TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses

JB. Marchand et al.AACR 2023Download the poster herePoster Presentation

Published 16 April 2023
Categorized as 2023, Invir.IO, Publication, TG6050-en

Extracellular vesicles (EV): mediators of therapeutic vaccination? In vivo and in vitro characterization of EVs generated after infection of human and murine cells with therapeutic poxviruses

L. Walther et al.AACR 2023Download the poster herePoster Presentation

Published 16 April 2023
Categorized as -others, 2023, Publication

Transgene’s Board of Directors Proposes the Appointment of Carol Stuckley, MBA, as New Independent Director

Appointment of Carol Stuckley as New Independent Director 15

Published 12 April 2023
Categorized as 2023, dates, dates, Press release

Availability of Preparatory Documents for the Combined General Meeting of May 5, 2023

Availability of Preparatory documents for the combined general meeting of May 5, 2023 15

Published 11 April 2023
Categorized as 2023, dates, dates, Press release

Availability of Transgene’s 2022 Universal Registration Document

Availability of Transgene’s 2022 Universal Registration Document 15

Published 6 April 2023
Categorized as 2023, dates, dates, Press release, TG4050

Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers

Transgene to host KOL webinar on TG4050 15

Published 4 April 2023
Categorized as 2023, dates, dates, Press release, TG4050

Transgene Announces Upcoming Investor Meetings

Transgene announces upcoming investor meetings 15

Published 27 March 2023
Categorized as 2023, dates, dates, Press release

Positive data on key clinical candidates delivered in 2022 – Promising outlook for 2023 as industry interest in therapeutic cancer vaccines and oncolytic viruses gains significant momentum

2022 full-year results and business update 15

Published 16 March 2023
Categorized as 2023, dates, dates, Press release

Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023

Transgene to present multiple posters highlighting the potential of its exciting immunotherapy pipeline at AACR2023 15

Published 15 March 2023
Categorized as 2023, dates, Press release, TG4001, TG4050, TG6002, TG6050-en

Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors

Transgene appoints John C Bell and Pedro Romero as Key Scientific advisors 15

Published 9 March 2023
Categorized as 2023, dates, dates, Press release

Posts pagination

Newer posts Page 1 … Page 15 … Page 47 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu